Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sangzhi alkaloids vs acarbose in type 2 diabetes mellitus with chronic kidney disease
ChiCTR2500115748Phase 4Not yet recruiting
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ramulus mori alkaloids in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) (2 arms), sponsored by Zhejiang Provincial People's Hospital. Primary endpoints: Urinary albumin-to-creatinine ratio (UACR) and Urinary alpha-1 microglobulin. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
ramulus mori alkaloids
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2500115748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115748.